Buscar
Galmed Pharmaceuticals Ltd
GLMDAñadir a la lista de seguimiento
0.570USD
-0.079-12.34%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
3.75MCap. mercado
PérdidaP/E TTM
Más Datos de Galmed Pharmaceuticals Ltd Compañía
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Información de Galmed Pharmaceuticals Ltd
Símbolo de cotizaciónGLMD
Nombre de la empresaGalmed Pharmaceuticals Ltd
Fecha de salida a bolsaMar 13, 2014
Director ejecutivoBaharaff (Allen)
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 13
Dirección16 Tiomkin Street
CiudadTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal6578317
Teléfono97236938448
Sitio Webhttps://www.galmedpharma.com
Símbolo de cotizaciónGLMD
Fecha de salida a bolsaMar 13, 2014
Director ejecutivoBaharaff (Allen)
Ejecutivos de Galmed Pharmaceuticals Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
13.96K
+77.62%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Galmed Pharmaceuticals Ltd?
Los cinco principales accionistas de Galmed Pharmaceuticals Ltd son: Mr. Allen Baharaff
¿Cuántas instituciones poseen acciones de Galmed Pharmaceuticals Ltd (GLMD)?
A fecha de 2026Q1, 30 instituciones poseen acciones de Galmed Pharmaceuticals Ltd, con un valor de mercado combinado de aproximadamente 224.38K, lo que representa el 3.40% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 75169.00.